Auna (NYSE:AUNA – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.42, Zacks reports. The firm had revenue of $336.67 million during the quarter, compared to analysts’ expectations of $1.08 billion. Auna had a return on equity of 13.52% and a net margin of 4.40%.
Auna Stock Performance
AUNA traded up $1.17 during trading on Wednesday, reaching $5.97. 1,228,828 shares of the company’s stock were exchanged, compared to its average volume of 446,339. Auna has a fifty-two week low of $4.46 and a fifty-two week high of $7.87. The company has a market capitalization of $441.54 million, a P/E ratio of 8.41 and a beta of 2.09. The company has a quick ratio of 0.82, a current ratio of 0.90 and a debt-to-equity ratio of 1.63. The business has a 50 day moving average price of $4.95 and a 200 day moving average price of $5.43.
Key Headlines Impacting Auna
Here are the key news stories impacting Auna this week:
- Positive Sentiment: Q4 beat — Auna reported Q4 EPS of $0.53 vs. the Zacks consensus $0.13 and topped revenue estimates, a clear near-term catalyst for upside. Auna S.A. Tops Q4
- Positive Sentiment: Raised revenue guidance — Management gave FY26 revenue guidance of about $1.4–$1.6 billion vs. a consensus near $1.3 billion, suggesting material top-line growth expectations. Auna Announces 4Q25 and FY25 Financial Results
- Positive Sentiment: Strong cash generation and 2026 targets — Company statement highlights robust FY25 cash flow and explicit 2026 growth targets, supporting the sustainability of the beat and guidance. Auna Posts Strong FY25 Cash Generation
- Positive Sentiment: Analyst acknowledgment and value recognition — Zacks added AUNA to its Rank #1 (Strong Buy) value list and several media pieces highlight the stock as a value/momentum pick, which can attract buy-side interest. Best Value Stocks to Buy
- Neutral Sentiment: Consensus rating — Analysts show a consensus “Moderate Buy,” indicating general support but not unanimous conviction. Consensus Rating
- Negative Sentiment: Short interest rose ~40% in February to 436,807 shares (≈0.6% of float), which could add volatility; however the short-interest days are low (~0.7), limiting sustained short pressure.
- Negative Sentiment: Liquidity and leverage — Trailing metrics show a current ratio ~0.90, quick ratio ~0.82 and debt/equity ~1.63, highlighting balance-sheet leverage that investors should monitor as growth ramps.
Hedge Funds Weigh In On Auna
Analyst Ratings Changes
Several research firms recently issued reports on AUNA. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Auna in a report on Monday, December 29th. Zacks Research upgraded shares of Auna from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, February 9th. Wall Street Zen raised shares of Auna from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. HSBC raised Auna from a “hold” rating to a “buy” rating and set a $6.90 price objective for the company in a report on Wednesday, January 21st. Finally, Jefferies Financial Group started coverage on shares of Auna in a research note on Friday, January 16th. They set a “buy” rating and a $9.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Auna currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.30.
View Our Latest Research Report on AUNA
Auna Company Profile
Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna’s organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints.
The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines.
See Also
- Five stocks we like better than Auna
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Auna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auna and related companies with MarketBeat.com's FREE daily email newsletter.
